Another comprehensive review of evidence, published last year in the journal Clinical Psychology Review, revealed that using cannabis may help people with alcohol or opioid dependencies to fight their addictions.
But this finding may be contentious; the National Academies of Sciences review suggests that cannabis use actually drives increased risk for abusing, and becoming dependent on, other substances.
Also, the more that someone uses cannabis, the more likely they are to develop a problem with using cannabis. Individuals who began using the drug at a young age are also known to be at increased risk of developing a problem with cannabis use.
Depression, post-traumatic stress disorder, and social anxiety
The review published in Clinical Psychology Review assessed all published scientific literature that investigated the use of cannabis to treat symptoms of mental illness.
Its authors found some evidence supporting the use of cannabis to relieve depression and post-traumatic stress disorder symptoms.
That being said, they caution that cannabis is not an appropriate treatment for some other mental health conditions, such as bipolar disorder and psychosis.
The review indicates that there is some evidence to suggest that cannabis might alleviate symptoms of social anxiety, but again, this is contradicted by the National Academies of Sciences, Engineering, and Medicine review, which instead found that regular users of cannabis may actually be at increased risk of social anxiety.
Cancer
Evidence suggests that oral cannabinoids are effective against nausea and vomiting caused by chemotherapy, and some small studies have found that smoked cannabis may also help to alleviate these symptomsTrusted Source.
Some studies on cancer cells suggest that cannabinoids may either slow down the growth of or kill some types of cancer. However, early studiesTrusted Source that tested this hypothesis in humans revealed that although cannabinoids are a safe treatment, they are not effective at controlling or curing cancer.
Multiple sclerosis
The short-term use of oral cannabinoids may improve symptoms of spasticity among people with multiple sclerosis, but the positive effects have been found to be modest.
Epilepsy
In June 2018, the Food and Drug Administration (FDA) approved the useTrusted Source of a medication containing cannabidiol (CBD) to treat two rare, severe, and specific types of epilepsy — called Lennox-Gastaut syndrome and Dravet syndrome — that are difficult to control with other types of medication. This CBD-based drug is known as Epidiolex.
CBD is one of many substances that occurs in cannabis. It is not psychoactive. The drug for treating these conditions involves a purified form of CBD. The approval was based on the findings of research and clinical trials.
A study published in 2017 found that the use of CBD resulted in far fewer seizures among children with Dravet syndrome, compared with a placebo.
Dravet syndrome seizures are prolonged, repetitive, and potentially lethal. In fact, 1 in 5 children with Dravet syndrome do not reach the age of 20 years.
In the study, 120 children and teenagers with Dravet syndrome, all of whom were aged between 2 and 18, were randomly assigned to receive an oral CBD solution or a placebo for 14 weeks, along with their usual medication.
You can Buy marijuana online discreet packaging by contacting the following
Text OR Call:....+1(707)742-3597
Wickr App:....Genlabs
EMAIL ;[email protected]
WhatsApp at:+1(312) 379-9621
For more info:www.ripe2pipeganjashop.com/
